» Articles » PMID: 16406864

Secondary Hormonal Therapy for Advanced Prostate Cancer

Overview
Journal J Urol
Publisher Wolters Kluwer
Specialty Urology
Date 2006 Jan 13
PMID 16406864
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Androgen ablation remains the cornerstone of management for advanced prostate cancer. Therapeutic options in patients with progressive disease following androgen deprivation include antiandrogen withdrawal, secondary hormonal agents and chemotherapy. Multiple secondary hormonal agents have clinical activity and the sequential use of these agents may lead to prolonged periods of clinical response. We provide a state-of-the-art review of the various agents currently used for secondary hormonal manipulation and discusses their role in the systemic treatment of patients with prostate cancer.

Materials And Methods: A comprehensive review of the peer reviewed literature was performed on the topic of secondary hormonal therapies, including oral antiandrogens, adrenal androgen inhibitors, corticosteroids, estrogenic compounds, gonadotropin-releasing hormone antagonists and alternative hormonal therapies for advanced prostate cancer.

Results: Secondary hormonal therapies can provide a safe and effective treatment option in patients with AIPC. The use of steroids and adrenolytics, such as ketoconazole and aminoglutethimide, has resulted in symptomatic improvement and a greater than 50% prostate specific antigen decrease in a substantial percent of patients with AIPC. A similar clinical benefit has been demonstrated with estrogen based therapies. Furthermore, these therapies have demonstrated a decrease in metastatic disease burden. Other novel hormonal therapies are currently under investigation and they may also show promise as secondary hormonal therapies. Finally, guidelines from the United States Food and Drug Administration Prostate Cancer Endpoints Workshop were reviewed in the context of developing new agents.

Conclusions: Secondary hormonal therapy serves as an excellent therapeutic option in patients with AIPC in whom primary hormonal therapy has failed. Practicing urologists should familiarize themselves with these oral medications, their indications and their potential side effects.

Citing Articles

Simultaneous Autophagy and Androgen Receptor Inhibition in a Prostate Cancer Xenograft Model.

Salemi S, Kranzbuhler B, Baumgartner V, Breitenmoser L, Kuzmanov A, Lehner F Cancers (Basel). 2024; 16(19).

PMID: 39409882 PMC: 11482627. DOI: 10.3390/cancers16193261.


Thiourea-functionalized aminoglutethimide derivatives as anti-leishmanial agents.

Sajid M, Siddiqui H, Zafar H, Yousuf S, Threadgill M, Choudhary M Future Med Chem. 2024; 16(15):1485-1497.

PMID: 38953461 PMC: 11370960. DOI: 10.1080/17568919.2024.2359362.


Apalutamide and autophagy inhibition in a xenograft mouse model of human prostate cancer.

Eberli D, Kranzbuhler B, Prause L, Baumgartner V, Preda S, Sousa R J Cancer Res Clin Oncol. 2022; 148(12):3351-3360.

PMID: 35751683 PMC: 9587065. DOI: 10.1007/s00432-022-04059-1.


Immunotherapeutic role of cabazitaxel treatment in the activation of TLR3 signalling in metastatic castration-resistant prostate cancer in vitro.

Deveci Ozkan A, Eskiler G, Kaleli S, Sahin E Mol Biol Rep. 2021; 49(2):1261-1271.

PMID: 34826050 DOI: 10.1007/s11033-021-06953-2.


Whole-body magnetic resonance imaging (WB-MRI) reporting with the METastasis Reporting and Data System for Prostate Cancer (MET-RADS-P): inter-observer agreement between readers of different expertise levels.

Pricolo P, Ancona E, Summers P, Abreu-Gomez J, Alessi S, Jereczek-Fossa B Cancer Imaging. 2020; 20(1):77.

PMID: 33109268 PMC: 7590732. DOI: 10.1186/s40644-020-00350-x.